Indirect and direct anticoagulants predominantly inhibiting factor Xa

Therapy

Volumn 5, Issue 2, 2008, Pages 177-192

  Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apixaban; DU 176d; Factor Xa inhibitors; Idraparinux; LY517717; Pulmonary embolism; Rivaroxaban; Thromboembolism; Thrombosis; YM150

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; AVE 5026; BIOTIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PLACEBO; PRT 054021; RIVAROXABAN; SR 123781; THROMBIN INHIBITOR; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; YM 150;

ACUTE CORONARY SYNDROME; ARTERY EMBOLISM; BIOTINYLATION; BLEEDING; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNSTABLE ANGINA PECTORIS; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

EID: 41949089934     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.2.177     Document Type: Review

References (40)

1. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116, 552-560 (2007).
2. Bates SM, Weitz JI: The status of new anticoagulants. Br. J. Haematol. 134, 3-19 (2006).
3. Eikelboom JW, Weitz JI: A replacement for warfarin: the search continues. Circulation 116, 131-133 (2007)
4. Saiah E, Soares C: Small molecule coagulation cascade inhibitors in the clinic. Curr. Top. Med. Chem. 5, 1677-1695 (2005).
5. Bauer KA: New anticoagulants. Hematology Am. Soc. Hematol. Educ. Prgram 450-456 (2006).
6. Turpie AGG: Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb Vasc. Biol. 27, 1238-1247 (2007).
7. Ma Q, Fareed J: Idraparinux sodium. Sanofi-Aventis. IDrugs 7, 1028-1034 (2004).
8. Herbert JM, Herault JP, Bernal A et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting pentasaccharide. Blood 91, 4197-4205 (1998).
9. Bijsterveld NR, Vink R, Van Arken BE et al.: Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide ldraparinux in healthy volunteers. Br. J. Haematol. 124, 653-658 (2004)
10. The PERSIST Investigators: A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a Phase II evaluation. J. Thromb. Haemost. 2, 47-53 (2004).
11. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 357, 1094-1104 (2007).
12. The van Gogh Investigators: Extended prophylaxis of venous thromboembolism with idraparinux. N. Engl. J. Med. 357, 1105-1112 (2007).
13. Harenberg J, Joerg I, Vukojevic Y, Weiss C, Mikus G: Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur. J. Clin. Pharmacol. (2008) (In press).
14. Harenberg J, Weiss C, Mikus G, Joerg I, Vukojevic Y: Long elimination half-life of idraparinux after termination of therapy explains bleeding in the van Gogh trials. J. Thromb. Haemost. (2008) (In press).
15. Savi F, Herault JP, Duchaussoy P et al.: Reversible biotinylated oligosaccharides, a new approach for a better management of the anticoagulant therapy. J. Thromb. Haemost. (Suppl.), Abstract P-W-645 (2007).
16. Lassen MR, Dahl OF, Mismetti P, Destrèe D: AV5026, a new anticoagulant for prevention of venous thromboembolism in total knee replacement surgery - TREK: a dose ranging study. Blood 110, Abstract 311 (2007).
17. Ansell J: Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. 5(Suppl. 1), 60-64 (2007).
18. Paccaly A, Frick A, Rohatagi S et al.: Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for Phase 2/3 simulation of exposure. J. Clin. Pharmacol. 46, 37-44 (2006).
19. Cohen M, Deepak L. Bhatt DL et al.; on behalf of the SEPIA-PCI Trial Investigators: Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa Inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial. Circulation 115, 2642-2651 (2007).
20. Rezaie AR: DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb. Haemost. 89, 112-121 (2003).
21. Dyke CK, Becker RC, Kleiman NS et al.: First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 105, 2385-2391 (2002).
22. Alexander JH, Yang H, Becker RC et al.; on behalf of the XANADU-ACS Investigators: First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XANADU-ACS trial. J. Thromb. Haemost. 3, 439-447 (2005).
23. Kubitza D, Haas S: Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs 15, 843-855 (2006).
24. Eriksson BI, Lars C, Borris LC et al.; for the ODIXa-HIP Study Investigators: A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114, 2374-2381 (2006).
25. Lassen MR, Turpie AG, Rosencher N et al.: Rivaroxaban - an oral, direct factor Xa inhibitor - for thromboprophylaxis after total knee arthroplasty: the RECORD3 trial. Blood 110, Abstract 308 (2007)
26. Kakkar AK, Brenner B, Dahl OE et al.: Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD2. Blood 110, Abstract 307 (2007).
27. Eriksson BI, Borris LC, Friedman RJ et al.: Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1. Blood 110, Abstract 6 (2007).
28. Mueck W, Agnelli G, Buller H: Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT). Blood 110, Abstract 1880 (2007).
29. Agnelli G, Gallus A, Goldhaber SZ et al.; for the ODIXa-DVT Study Investigators: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT Study. Circulation 116, 180-187 (2007).
30. Buller HR: Once-daily treatment with an oral, direct factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-finding study. Eur. Heart J. 27, 761 Abstract (2006).
31. Pinto DJ, Orwat MJ, Koch S et al.: Discovery of 1-(4-Methoxyphenyl) -7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H- pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339-5356 (2007).
32. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D: The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (2007).
33. Buller HR: A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli investigators. J. Thromb. Haemost. (Suppl.), Abstract O-S-003 (2007).
34. Iwatsuki Y, Shigenaga T, Moritani Y et al.: Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. Blood 108, Abstract 911 (2006).
35. Eriksson BI, Turpie AGG, Lassen MR et al.; for the Onyx Study Group: A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J. Thromb. Haemost. 5, 1660-1665 (2007).
36. Eriksson BI, Turpie AGG, Lassen MR et al.: Once daily YM150, an oral direct factor Xa inhibitor, for prevention of venous thromboembolism in patients undergoing elective primary hip relpacement. Blood 110, Abstract 309 (2007).
37. Norman P: Medicinal Chemistry - 12th RSC-SCI Symposium (Part I), Enzyme Inhibitors. IDdb Meeting Report, Cambridge, UK (2003).
38. Agnelli G, Haas SK, Krueger KA, Ginsberg JS, Dmitrienko A, Brandt JT: A Phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. J. Thromb. Haemost. 5, 746-753 (2007).
39. Zafar MU, Vorchheimer DA, Gaztanaga J et al.: Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb. Haemost. 98, 883-888 (2007).
40. Abe K, Siu G, Edwards S et al.: Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral Factor Xa inhibitor. Blood. 108, Abstract 901 (2006).